ONKOS SURGICAL’s 3rd annual partnership with MSTS kicks off at the AAOS annual meeting in New Orleans

ONKOS SURGICAL’s 3rd Annual Partnership with MSTS Kicks Off at the AAOS Annual Meeting in New Orleans

Onkos Surgical® has renewed our diamond level sponsorship with the MSTS for 2018. This marks the second year of our partnership with the society. Onkos continues to focus our innovation initiatives in three areas: 1) infection management, 2) aseptic loosening and 3) soft tissue management.

Our sponsorship of the MSTS is another strong signal that Onkos is committed and aligned to the msts mission of advancing the science of orthopedic oncology and promoting high standards of patient care through excellence in education and research.

Patrick Treacy, Onkos CEO and Cofounder said, “our partnership with the MSTS is a foundational investment for Onkos Surgical. Collaboration with the society and its membership is critical for our team to understand the unique challenges orthopedic oncologists and their patients face. It is this dialog that will provide the necessary insights we need to truly innovate for this community of surgeons and patients.” Abu Muhammad, Society Director for the MSTS, said, “we are pleased to partner with Onkos Surgical at the Diamond level. The mission of our organization cannot be realized without the generous support of our sponsors. We look forward to working with the team at Onkos.”
 


ONKOS IN THE NEWS

ONKOS SURGICAL® and 3D Systems Team To Advance Personalized Surgical Oncology Solutions

PARSIPPANY, NJ, March 6, 2018 -Onkos Surgical, Inc. Announced today that it signed a 4-year agreement with 3D Systems (NYSE:DDD) to advance the delivery of personalized surgical solutions and help improve patient outcomes. The agreement provides Onkos Surgical priority access to 3D Systems’ VSP® (Virtual Surgical Planning) Orthopedic product line for surgical planning, as well as 3D printed anatomical models. Additionally, the companies will collaborate on next-generation 510(k) clearances for 3D printed implants and instruments for tumor reconstruction.

Through this partnership, the companies aim to advance the delivery of personalized surgical solutions to help improve outcomes for patients with tumors and lesions occurring in the pelvis and long bones (i.e., the large bones found in the arms and legs) associated with musculoskeletal cancers. The combination of VSP and 3D printing allows surgeons to preoperatively plan a surgical procedure, as well as design surgical tools and implants for each patient’s unique case.

Established by 3D systems, VSP technology received FDA market clearance for the cranio-maxillofacial region as a service-based approach to personalized surgery, combining expertise in medical imaging, surgical simulation and 3D printing. The surgeon initiates the process, bringing their clinical knowledge and desired surgical plan to an online web meeting with a 3D systems biomedical engineer to simulate and plan the surgical procedure. The outcome is a digital plan that is transferred to the operating room via accurate 3D printed patient-specific models, guides and templates.

“We are delighted to announce this partnership with 3D Systems, a true visionary and leader in medical device 3D printing and surgical planning,” said Patrick Treacy, co-founder and chief executive officer, Onkos Surgical. “As an early stage investor in Onkos, they understand the criticality of our connection to the customer, the unique challenges these surgeons and patients face and the tremendous opportunity we have to make a difference for these patients while building a high value and scalable business.”

Onkos surgical was founded in 2015 to deliver high quality implants and instruments that meet the unique needs of musculoskeletal tumor patients. The company quickly embraced 3D printing as a technology that could address the particular needs of both the cancer patient, and the cancer surgeon. Onkos surgical realized the profound impact they could make if they combined personalized 3D printed medical devices and instrumentation with patient-specific surgical simulation.

“When we launched our Precision Oncology initiative at MSTS 2017 in Denver, it was met with great enthusiasm from the surgeon community,” said Sean Curry, senior vice president of commercial operations, Onkos Surgical. “The relationship with 3D Systems enhances our capabilities with product bundles and patient-specific solutions that will deliver on our promise of bringing focus and dedication to this space.”

“3D Systems is pleased to partner with Onkos Surgical delivering adaptive tools designed to provide insights, processes and outcomes for musculoskeletal oncology cases,” said Kevin McAlea, executive vice president, general manager, Metals and Healthcare, 3D Systems. “The combination of VSP and 3D printing provides an advantage for surgeons to personalize the surgical plan, instruments and implants for each unique case.”

According to the NIH – National Cancer Institute (cancer.gov), there were 3,260 new primary bone cancer cases reported in 2017. In addition to chemotherapy and radiation, two common surgical options for musculoskeletal cancer patients are amputation and limb salvage. Through limb salvage, the surgeon removes the cancer and some healthy tissue with the goal of leaving the limb largely intact. The section of bone that was removed can be replaced either with a bone graft from the patient or another person, or with an internal prosthesis (i.e., implants) made of metal and other materials.


Forward-looking statements

Certain statements made in this release that are not statements of historical or current facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the company to be materially different from historical results or from any future results or projections expressed or implied by such forward-looking statements. In many cases, forward looking statements can be identified by terms such as “believes,” “belief,” “expects,” “may,” “will,” “estimates,” “intends,” “anticipates” or “plans” or the negative of these terms or other comparable terminology. Forward-looking statements are based upon management’s beliefs, assumptions and current expectations and may include comments as to the company’s beliefs and expectations as to future events and trends affecting its business and are necessarily subject to uncertainties, many of which are outside the control of the company. The factors described under the headings “forward-looking statements” and “risk factors” in the company’s periodic filings with the securities and exchange commission, as well as other factors, could cause actual results to differ materially from those reflected or predicted in forward-looking statements. Although management believes that the expectations reflected in the forward-looking statements are reasonable, forward-looking statements are not, and should not be relied upon as a guarantee of future performance or results, nor will they necessarily prove to be accurate indications of the times at which such performance or results will be achieved. The forward-looking statements included are made only as the date of the statement. 3D Systems undertakes no obligation to update or review any forward-looking statements made by management or on its behalf, whether as a result of future developments, subsequent events or circumstances or otherwise.

About 3D Systems

Systems3D Systems provides comprehensive 3D products and services, including 3D printers, print materials, on demand manufacturing services and digital design tools. Its ecosystem supports advanced applications from the product design shop to the factory floor to the operating room. 3D systems’ precision healthcare capabilities include simulation, virtual surgical planning, and printing of medical and dental devices as well as patient-specific surgical instruments. As the originator of 3D printing and a shaper of future 3D solutions, 3D Systems has spent its 30-year history enabling professionals and companies to optimize their designs, transform their workflows, bring innovative products to market and drive new business models. More information on the company is available at www.3dsystems.com.


ONKOS SURGICAL® Announces Major Milestone with First Patient Entered in the Onkos Registry

PARSIPPANY, NJ, March 8, 2018 -Onkos Surgical, Inc., a specialty medtech company dedicated to advancing innovation for the surgical oncology market, announced today that Dr. Steven Gitelis and Rush University has entered the first patient in the Surgical Oncology Registry Team (SORT™) or Onkos’s Registry. SORT™ is a multicenter, cloud based, HIPAA compliant platform designed to prospectively collect functional, psychosocial and oncological outcomes.

“This is a major milestone for Onkos and the musculoskeletal oncology community of surgeons and patients. When we started our company, we made a commitment that we would place a large investment in collecting prospective outcomes in this space,” said Patrick Treacy CEO and co-founder of Onkos Surgical. “SORT™ is a cloud-based platform that will allow surgeons to collect prospective data and collaborate with other institutions to drive larger data sets. We are the first and only company to invest in a registry of this kind and we believe this database will allow clinicians to answer meaningful questions that may lead to improved patient outcomes.”

Steven Gitelis, MD, Onkos Surgical Chief Medical Officer and Surgeon in Chief and Director, Section of Orthopedic Oncology at Rush University said, “This is an unprecedented opportunity for my musculoskeletal oncology colleagues to collaborate in a way that will answer important questions. The Onkos Registry provides a research platform that will enable individual institutions to prospectively collect their own data while partnering with other leading institutions around the country to answer questions that will potentially impact how we treat patients in the future. In the past, small data sets have impacted the ability to truly change the paradigm of patient care. This registry has the potential to change that.”

“We have several leading cancer institutions around the country who are interested in this platform,” said Jerry D’Alessio, Onkos VP of R&D and Advanced Engineering. We spent a tremendous amount of time perfecting the protocol and analytical tools to enable surgeons to prospectively assess functional, psychosocial and oncologic outcomes. The cloud-based platform allows the surgeons to design prospective studies and enables patients to participate in the analysis of their outcomes. We are excited to expand this registry over the coming year.”

Mr. Treacy added, “Onkos has made a commitment to musculoskeletal oncology. We continue to make investments that will advance innovation and we know that our singular and dedicated focus to this group of surgeons and patients may lead to meaningful improvements in patient care.”


ONKOS INNOVATION SERIES

ONKOS SURGICAL® Tackles Significant Clinical Challenge: Aseptic Loosening

Aseptic loosening of endoprostheses continues to be a substantial clinical challenge for orthopedic oncologists and the patients they treat1. While improvements in implant design have helped, surgeons continue to search for new solutions to solve for aseptic loosening in a patient population with compromised healing potential2. Fortunately, there have been technological advances such as additive manufacturing (3D printing) and methods to apply hydroxyapatite (HA) to three-dimensional pore structures that may help to address this clinical challenge.

A recent publication by Mumith et al. Suggests there are opportunities to obtain improved fixation for endoprostheses with the use of stems designed to incorporate porous metal extracortical collars. This is significant, considering a large number of patients with distal femoral and proximal tibial endoprostheses require a revision due to implant loosening3. The results of this research provided two key insights for future implant designs to potentially address this challenge. First, the authors found that optimal tissue ingrowth is heavily dependent on pore size. Second, they noted that HA coatings, when deposited on a porous metal implant in a manner such that the implant remains porous, can have hydrophilic properties. This allows the implant to absorb and deliver blood or other biological fluids to the endogenous, healthy bone at the implant interface. The research concluded that a collar design with a specific porosity to maximize bone ingrowth, coupled with a HA coating applied in this certain way, may promote extracortical bone bridging1.

Onkos Surgical is currently focused on three distinct clinical areas of innovation aligned with the most common failure modes of limb salvage implants: 1) Infection, 2) soft tissue management and 3) aseptic loosening1. We have invested heavily in developing experience and expertise in 3D printing and application of HA. We believe, combined with our singular focus on providing solutions for musculoskeletal oncologists and their patients, this provides us with the ability to develop new implant designs to address aseptic loosening.

We have also partnered with clinicians at leading cancer institutions to guide our development initiatives. We are specifically interested in understanding the clinical factors that impact patient outcomes and the nuances of the surgical workflow to optimize or efficiency. In a recent meeting with Shervin Oskouei, MD, Assistant Professor of Orthopedic Surgery at Emory University School of Medicine, we discussed his thoughts on aseptic loosening and implant design.

Dr. Oskouei, can you share your thoughts on the challenges associated with aseptic loosening in your patient population?

“Similar to the results in arthroplasty patients, implants used in oncology applications have a high failure rate due to aseptic loosening. Especially as patients survive longer, I suspect we will continue to see a rise in failures from loosening.”

What are some implant design factors that you believe are important in minimizing this complication?

“The reduction of polyethylene wear debris and inability of polyethylene debris to gain access to the canal of the long bone in oncology implants is crucial. Similar to the findings in the Mumith study, there is merit in providing a solution where the collars will be able to be matched to the patients’ cross sectional diameter for ideal fit and bone ingrowth. I think we need to look to biologic fixation of our implants to bone as an ideal way to reduce aseptic loosening including press-fit stems to allow a biologic fixation with constant remodeling of the implant-bone interface.”

At Onkos, we are currently focusing development efforts on a family of stems with HA coating to address the clinical challenge of loosening (figure 1). We believe this may have the potential to provide an optimal environment for bone and soft tissue attachment, improve extracortical fixation, and reduce the incidence of implant revisions due to loosening.

The products described in this article are not cleared by the FDA for commercial use in the United States.

Fig. 1. Optimized pore structure with HA deposition. Representative image, not available for commercial sale in US.

References:
1. Eric R. Henderson, et al. Failure Mode Classification for Tumor Endoprostheses: Retrospective Review of Five Institutions and a Literature Review. The Journal of Bone & Joint Surgery. Volume 93-A d No.5, March 2, 2011.

2. P.S Unwin, et al. Aseptic Loosening in cemented custom-made prosthetic replacements for bone tumors of the lower limb. The Journal of Bone and Joint Surgery. Volume 78-B, No.1, January 1996.

3. A. Mumith, et al. Augmenting the osseointegration of endoprostheses using laser-sintered porous collars. The Bone & Joint Journal. Volume 99-B, No.2, February 2017.


ONKOS SURGICAL® Featured in MedTech Strategist

Key points

• The musculoskeletal oncology market has long been a niche of a niche, woefully under-served by large orthopedic companies, which often forces surgeons to improvise the tools and implants they need to treat patients.

• Launched just over two years ago, Onkos Surgical is building a company focused exclusively on this segment, basing its business on a deep relationship with surgeons who have historically felt ignored by product companies.

• The company has been able to move quickly and efficiently by embracing a strategy it calls “specialty medtech” as well as a novel approach to manufacturing using 3D printing. It is also building through partnerships, including one with 3D pioneer 3D Systems.

• Onkos is already thinking of ways it can expand its business, but perhaps its greatest challenge: proving to this often-neglected customer base that it’s different from other orthopedic companies and that its commitment to the field is real.

To read this January issue of the MedTech Strategist featuring Onkos Surgical go to: http://onkossurgical.com/onkos_medtech_article_1-31-18.pdf


ONKOS PRODUCT HIGHLIGHT

uDesign™ Patient Solutions

uDesign Patient Solutions is a consultative, concierge level service provided by ONKOS SURGICAL. uDesign brings the level of expertise and surgical planning you demand in complex cases to each and every one of your cases. The interactive experience enables a personalized planning approach for each patient allowing you to better manage your outcomes.

My3D™ Technologies

Differentiated service model to support My3D personalized solutions:

  • Cloud based platform for surgeon to share imaging and create a digital surgical plan.
  • With Onkos assistance, surgeon creates a simulated surgical experience and plan.
  • Engineers create a suggested plan based on surgeon’s desires.
  • Includes a suite of capabilities.

Sample uDesign™ Surgical Plan


ONKOS ADVOCATES

Onkos Surgical is committed to help raise awareness of sarcoma and pediatric cancer through fundraising activities, support of cancer research, and partnerships with organizations and regulatory agencies to advocate for change that will impact the lives of cancer patients.

Sarcoma Foundation of America
According to its website, “The mission of the Sarcoma Foundation of America (SFA) is to advocate for sarcoma patients by funding research and by increasing awareness about the disease. The organization raises money to privately fund grants for sarcoma researchers and conducts education and advocacy efforts on behalf of sarcoma patients.” To learn more about the Sarcoma Foundation of America please visit www.curesarcoma.org

American Cancer Society
According to its website, “At the American Cancer Society, we’re on a mission to free the world from cancer. Until we do, we’ll be funding and conducting research, sharing expert information, supporting patients, and spreading the word about prevention. All so you can live longer—and better.” To learn more about the American Cancer Society please visit www.cancer.org


ONKOS SURGICAL® Participates in Race to Cure Sarcoma 5K Run

On November 12, 2017, Onkos employees participated in a 5K charity run to support sarcoma awareness. The event was sponsored by the Sarcoma Foundation of America-New Jersey and was well attended with over 100 participants. All proceeds were donated to the Sarcoma Foundation to advance research for musculoskeletal disorders. Despite the temperature being a bit chilly, everyone participating enjoyed supporting a great cause


ONKOS SURGICAL® Participates in Jersey Mike’s “Month of Giving” Initiative

On March 8th, ONKOS employees joined in on Jersey Mike’s Subs 8th Annual Day of Giving. Each year, “approximately
1,360 Jersey Mike’s restaurants donate 100 percent of sales to the local charities.” This year the make-a-wish foundation is the charity of choice at the Jersey Mike’s near the Onkos home office in Parsippany, NJ. According to its website, “over $6 million was donated to local charities” based on collections at each of the locations. At Onkos we continue to honor our commitment to support local and national organizations who share in making a difference in peoples lives. For more information, go to: www.jerseymikes.com/mog/charities


Onkos Surgical® and 3D Systems Team to Advance Personalized Surgical Oncology Solutions

PARSIPPANY, New Jersey, March 6, 2018 – Onkos Surgical, Inc. announced today that it signed a 4-year agreement with 3D Systems (NYSE: DDD) to advance the delivery of personalized surgical solutions and help improve patient outcomes. The agreement provides Onkos Surgical priority access to 3D Systems’ VSP® (Virtual Surgical Planning) Orthopedic product line for surgical planning, as well as 3D printed anatomical models. Additionally, the companies will collaborate on next-generation 510(k) clearances for 3D printed implants and instruments for tumor reconstruction.

Through this partnership, the companies aim to advance the delivery of personalized surgical solutions to help improve outcomes for patients with tumors and lesions occurring in the pelvis and long bones (i.e., the large bones found in the arms and legs) associated with musculoskeletal cancers. The combination of VSP and 3D printing allows surgeons to preoperatively plan a surgical procedure, as well as design surgical tools and implants for each patient’s unique case.

Established by 3D Systems, VSP technology received FDA market clearance for the cranio-maxillofacial region as a service-based approach to personalized surgery, combining expertise in medical imaging, surgical simulation and 3D printing. The surgeon initiates the process, bringing their clinical knowledge and desired surgical plan to an online web meeting with a 3D Systems biomedical engineer to simulate and plan the surgical procedure. The outcome is a digital plan that is transferred to the operating room via accurate 3D printed patient-specific models, guides and templates.

“We are delighted to announce this partnership with 3D Systems, a true visionary and leader in medical device 3D printing and surgical planning,” said Patrick Treacy, co-founder and chief executive officer, Onkos Surgical. “As an early stage investor in Onkos, they understand the criticality of our connection to the customer, the unique challenges these surgeons and patients face and the tremendous opportunity we have to make a difference for these patients while building a high value and scalable business.”
Onkos Surgical was founded in 2015 to deliver high quality implants and instruments that meet the unique needs of musculoskeletal tumor patients. The company quickly embraced 3D printing as a technology that could address the particular needs of both the cancer patient, and the cancer surgeon. Onkos Surgical realized the profound impact they could make if they combined personalized 3D printed medical devices and instrumentation with patient-specific surgical simulation.
“When we launched our Precision Oncology initiative at MSTS 2017 in Denver, it was met with great enthusiasm from the surgeon community,” said Sean Curry, senior vice president of commercial operations, Onkos Surgical. “The relationship with 3D Systems enhances our capabilities with product bundles and patient-specific solutions that will deliver on our promise of bringing focus and dedication to this space.”

“3D Systems is pleased to partner with Onkos Surgical delivering adaptive tools designed to provide insights, processes and outcomes for musculoskeletal oncology cases,” said Kevin McAlea, executive vice president, general manager, Metals and Healthcare, 3D Systems. “The combination of VSP and 3D printing provides an advantage for surgeons to personalize the surgical plan, instruments and implants for each unique case.”

According to the NIH – National Cancer Institute (cancer.gov), there were 3,260 new primary bone cancer cases reported in 2017. In addition to chemotherapy and radiation, two common surgical options for musculoskeletal cancer patients are amputation and limb salvage. Through limb salvage, the surgeon removes the cancer and some healthy tissue with the goal of leaving the limb largely intact. The section of bone that was removed can be replaced either with a bone graft from the patient or another person, or with an internal prosthesis (i.e., implants) made of metal and other materials.

Forward-Looking Statements
Certain statements made in this release that are not statements of historical or current facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the company to be materially different from historical results or from any future results or projections expressed or implied by such forward-looking statements. In many cases, forward looking statements can be identified by terms such as “believes,” “belief,” “expects,” “may,” “will,” “estimates,” “intends,” “anticipates” or “plans” or the negative of these terms or other comparable terminology. Forward-looking statements are based upon management’s beliefs, assumptions and current expectations and may include comments as to the company’s beliefs and expectations as to future events and trends affecting its business and are necessarily subject to uncertainties, many of which are outside the control of the company. The factors described under the headings “Forward-Looking Statements” and “Risk Factors” in the company’s periodic filings with the Securities and Exchange Commission, as well as other factors, could cause actual results to differ materially from those reflected or predicted in forward-looking statements. Although management believes that the expectations reflected in the forward-looking statements are reasonable, forward-looking statements are not, and should not be relied upon as a guarantee of future performance or results, nor will they necessarily prove to be accurate indications of the times at which such performance or results will be achieved. The forward-looking statements included are made only as the date of the statement. 3D Systems undertakes no obligation to update or review any forward-looking statements made by management or on its behalf, whether as a result of future developments, subsequent events or circumstances or otherwise.

About Onkos Surgical
Based in Parsippany, NJ., Onkos Surgical is a privately held surgical oncology company founded in 2015. Onkos Surgical believes surgical oncology deserves attention, focus and innovation. Through dedication and strategic partnerships, Onkos Surgical will advance surgical oncology solutions and advocate for and support the surgeons and caregivers that dedicate their lives to the surgical treatment of cancer. For more information, visit www.onkossurgical.com

About 3D Systems
3D Systems provides comprehensive 3D products and services, including 3D printers, print materials, on demand manufacturing services and digital design tools. Its ecosystem supports advanced applications from the product design shop to the factory floor to the operating room. 3D Systems’ precision healthcare capabilities include simulation, Virtual Surgical Planning, and printing of medical and dental devices as well as patient-specific surgical instruments. As the originator of 3D printing and a shaper of future 3D solutions, 3D Systems has spent its 30-year history enabling professionals and companies to optimize their designs, transform their workflows, bring innovative products to market and drive new business models. More information on the company is available at www.3dsystems.com.

Onkos Surgical® Announces Major Milestone with First Patient Entered in the Onkos Registry

Parsippany, NJ. , March 8, 2018 – Onkos Surgical, Inc., a specialty medtech company dedicated to advancing innovation for the surgical oncology market, announced today that Dr. Steven Gitelis and Rush University has entered the first patient in the Onkos Registry. The Onkos Registry is a multicenter, cloud based, HIPPA compliant platform designed to prospectively collect functional, psychosocial and oncological outcomes.

“This is a major milestone for Onkos and the musculoskeletal oncology community of surgeons and patients. When we started our company, we made a commitment that we would place a large investment in collecting prospective outcomes in this space,” said Patrick Treacy CEO and Co-founder of Onkos Surgical. “The Onkos Registry is a cloud-based platform that will allow surgeons to collect prospective data and collaborate with other institutions to drive larger data sets. We are the first and only company to invest in a registry of this kind and we believe this database will allow clinicians to answer meaningful questions that may lead to improved patient outcomes.”

Steven Gitelis, MD, Onkos Surgical Chief Medical Officer and Surgeon in Chief and Director, Section of Orthopedic Oncology at Rush University said, “This is an unprecedented opportunity for my musculoskeletal oncology colleagues to collaborate in a way that will answer important questions. The Onkos Registry provides a research platform that will enable individual institutions to prospectively collect their own data while partnering with other leading institutions around the country to answer questions that will potentially impact how we treat patients in the future. In the past, small data sets have impacted the ability to truly change the paradigm of patient care. This registry has the potential to change that.”

“We have several leading cancer institutions around the country who are interested in this platform,” said Jerry D’Alessio, Onkos VP of R&D and Advanced Engineering. We spent a tremendous amount of time perfecting the protocol and analytical tools to enable surgeons to prospectively assess functional, psychosocial and oncologic outcomes. The cloud-based platform allows the surgeons to design prospective studies and enables patients to participate in the analysis of their outcomes. We are excited to expand this registry over the coming year.”

Mr. Treacy added, “Onkos has made a commitment to musculoskeletal oncology. We continue to make investments that will advance innovation and we know that our singular and dedicated focus to this group of surgeons and patients may lead to meaningful improvements in patient care.”

About Onkos Surgical
Based in Parsippany, NJ., Onkos Surgical is a privately held surgical oncology company founded in 2015. Onkos Surgical believes surgical oncology deserves attention, focus and innovation. Through dedication and strategic partnerships, Onkos Surgical will advance surgical oncology solutions and advocate for and support the surgeons and caregivers that dedicate their lives to the surgical treatment of cancer.

ONKOS SURGICAL® is ecstatic to be partnered with the Musculoskeletal Tumor Society in 2017

blog

ONKOS SURGICAL® is ecstatic to be partnered with the Musculoskeletal Tumor Society in 2017

blogJuly was Sarcoma Awareness Month and we couldn’t think of a better time to honor the esteemed members of the Musculoskeletal Tumor Society (MSTS) and the work they do on a day to day basis. The members of the MSTS and the patients they treat, is quite simply why ONKOS SURGICAL exists. The MSTS released their Summer newsletter to all active members. The ONKOS ad shown ran in their Summer newsletter.

Onkos is also a sponsor at the MSTS Annual Meeting that was held on September 27-29, 2017 in Denver, CO. You can learn more about MSTS by visiting: msts.org.


BlogAt this year’s MSTS, ONKOS SURGICAL presented the following Product Theater Sessions:

Thursday, September 28th: PRECISION Oncology from ONKOS SURGICAL; Presenter: Joel Mayerson, MD (Professor of Orthopaedics; Chief, Division of Musculoskeletal Oncology; Director, Orthopaedic Residency Program at The Ohio State University)

Friday, September 29th: Infection Management; Presenter: Nicholas Bernthal, MD (Chief of Musculoskeletal Oncology at UCLA and faculty member at Orthopaedic Institute for Children)

Great collaborative effort for our Proforma team on the ONKOS Surgical Booth at the MSTS 2017 Annual Meeting.Every tumor is different and on occasion, incorporating a biologic in surgery may be necessary. GenVie™ Regenerative Biologics with uDesign™ from ONKOS SURGICAL® allows you to include the biologic of your choice in the pre-op plan, so you know exactly what will be on hand in the OR.

PRECISION Oncology and GenVie with uDesign was presented at the 2017 MSTS in Denver, Colorado.


ELEOSTM Limb Salvage System

Good is not good enough for your patients. ONKOS SURGICAL has a singular commitment to advancing innovation that will dramatically impact the lives of your patients. Introducing ELEOSTM, the modular limb salvage system that is indicated for procedures where radical resection and replacement of the distal femur, proximal femur, proximal tibia or total femur is required. The design combines OPERATIVE SIMPLICITY with a PROVEN DESIGN in one comprehensive,interchangeable system.

OPERATIVE SIMPLICITY
Quick-connect, modular trial components accurately replicate the length of the actual ELEOS implants, so that trial reduction is simply performed with greater stability and confidence. ELEOS offers a wide array of both cemented and canal filling stem options to meet surgeon preferences and increase intraoperative flexibility.
When needed, the modularity of the ELEOS system easily allows for intra-operative flexibility offering additional options for stems, tibial augments and compatible acetabular components.

blog

PROVEN DESIGN
An independent study1 validates the biomechanical stability, reducing instability and implant dislocation.
Inter-component strength is achieved by utilizing a simple to assemble male/female taper implant locking mechanism. If need be, component isassembly is just as simple by utilizing proprietary instrumentation to disengage tapers. Compared to other hinge knee designs that impede normal kinematics in deep flexion, ELEOS features a 5° valgus angle to assist in the restoration of patellofemoral kinematics and a deepened patella groove coupled with a hinge component designed to accommodate relief, reducing patellar subluxation and promoting normal loading patterns.

1. William G. Ward, MD; David Haight, MD; Paul Ritchie, MD; Stan Gordon, BS; Jeffrey J. Eckardt, MD; Dislocation of Rotating Hinge Total Knee Prostheses J Bone Joint Surg Am, 2003 Mar; 85 (3): 448 -453


author-imgDr. Nickolas B. Reimer

ELEOS with uDesignTM from ONKOS SURGICAL: A Surgeon’s Early Experience.

“My practice is varied procedurally, forcing me to solve many different clinical issues, intraoperatively.” said Nic Reimer of the Winship Cancer Center at Emory University School of Medicine in Atlanta, GA. “ELEOS™ with uDesign™ allows for extensive modularity, along with the ideal level of simplicity – the system is well thought out. uDesign leverages the simplicity of ELEOS, allowing me to understand exactly what to expect in surgery, well before I walk into the OR. I’m looking forward to future innovation from ONKOS SURGICAL® around the system, taking modular segmental systems further than ever before.”

Nickolas B. Reimer, MD, is a fellowship-trained orthopedic oncologist. His clinical practice focuses on the treatment of bone and soft tissue sarcomas, as well as benign bone and soft tissue tumors, in children and adults. In addition to primary soft tissue and bone tumors, he also treats metastatic disease affecting the musculoskeletal system. Since his practice often requires advanced, unconventional solutions to difficult problems, he also performs complex reconstruction and deformity correction surgery in non-oncologic patients.


GenVieTM Regenerative Biologics

blogONKOS SURGICAL was founded to bring focus and innovation to the musculoskeletal oncology. GenVieTM Regenerative Biologics includes a suite of biologic products with applications specific to musculoskeletal oncology and healing.

CYGNUSTM: Amniotic Tissue Matrix

VIA GRAFTTM: Allogenic Bone Allograft

ALLOGRAFTSTM: Wide range of allografts used for the reconstruction of the muscular system.


ONKOS SURGICAL Partners with PatientIQ to Launch Clinical Registry for Surgical Oncology Patients

PARSIPPANY , N.J., March 14, 2017 /PRNewswire/ — Onkos Surgical, an innovative surgical oncology company, has announced today it has partnered with PatientIQ, a healthcare data, research and analytics technology company, to launch a platform for the collection of clinical data for surgical oncology patients.

“Onkos Surgical has a singular commitment to advancing innovation that will dramatically change the lives of surgical oncology patients. Providing innovation comes with the responsibility of collecting clinical data that will help surgeons track and report on meaningful outcomes measurements,” said Patrick Treacy, Founder and CEO. “The partnership with PatientIQ provides Onkos with a HIPAA compliant, cloud-based application that seamlessly integrates clinical data, patient-reported outcomes and analytics for the various stakeholders in the value chain of patient care. This is another example of how Onkos is committed to investing in the surgical oncology space to drive innovation and change the status quo for surgical oncologists and the patients they care for.”

“The Onkos Registry aims to provide data driven insights with the systematic collection of outcomes data. The platform will create a secure environment for surgeons and patients to collaborate on clinical data points that will lead to advancements in out comes measurement for this challenging patient population,” said Sean Curry, SVP Commercial Operations. The company expects to launch the platform starting in Q2 at select institutions across the country.

About PatientIQ
PatientIQ is a Chicago based healthcare technology company with a proprietary, HIPAA compliant, cloud-based application that seamlessly integrates clinical data from the EHR, patient-reported outcomes (PROs), and provides analytics for the various stakeholders involved in the healthcare ecosystem.

For more information, visit https://patientiq.io/


ONKOS Named One of the 10 Hottest Medtech Startups of 2017

Onkos Surgical is a specialty medtech company focused on surgical oncology. It has a technology portfolio aimed at utilizing 3D printing capabilities, limb restoration tools, biologic solutions and more to help cancer patients. The suite of technologies is enabled by a service and surgical planning platform called uDesign PATIENT SOLUTIONS.

uDesign is a consultative, concierge level service for surgeons enabling personalized planning for each pa
tient. Additional technologies include the ELEOS Limb Salvage System for procedures where radical resection and replacement of the distal femur, proximal femur, proximal tibia or total femur is required. Every tumor is different. Using uDesign, my3D Technology from ONKOS SURGICAL allows the surgeon to utilize a personalized, 3D printed anatomic model that replicates their patients’ anatomy, allowing for better visualization of complex anatomic structures before, during and after surgery.

Highly qualified image processors segment CT scans to create 3D computer models of the hard and soft (tumor) tissue. The models are then reviewed by the surgeon in partnership with technical experts to generate essential preoperative and intra-operative surgical solutions, allowing the surgeon to better manage individual patient outcomes.

In April, the company announced that it closed a $17.6 million round of Series B funding.


ONKOS SURGICAL® is pleased to announce the appointment of renowned orthopaedic oncologist, Steven Gitelis, MD as Medical Director

Dr. GitelisDr. Gitelis will assist the company in expanding upon its core culture of advancing innovation to address clinical challenges in surgical oncology.

Dr. Gitelis is a fellowship-trained orthopaedic surgeon and experienced healthcare administrator. He is Chief of Surgery and Director of the Rush enter for Limb Preservation at the Rush University Medical Center (Chicago, IL). His numerous appointments also include Endowed Chair, Rush Medical College Professor of Orthopedic Oncology and Director, Section of Orthopedic Oncology, Rush-Presbyterian-St. Luke’s Medical Center. Dr. itelis has enjoyed a long-standing relationship with Rush, completing both his orthopaedic surgery residency and general surgery internship at Rush-Presbyterian- St. Luke’s Medical Center. He completed his fellowship at the prestigious Rizzoli Institute (Bologna, Italy) and Mayo Clinic (Rochester, MN).

“ONKOS SURGICAL is proud to have Dr. Gitelis work with us in the capacity of Medical Director,” said Patrick Treacy, Co-founder and CEO of ONKOS. “Building a company requires many talents. Building a medical device company with a singular focus in surgical oncology requires we have a Medical Director who understands the unique needs and challenges of all stakeholders in the healthcare community in which we serve. Dr. Gitelis’ reputation as a leader in the musculoskeletal oncology space is impeccable and we know his experience and expertise will help us shape ONKOS SURGICAL into a very important innovator in this space.”

“I am thrilled to be a part of the ONKOS SURGICAL team as we continue to innovate and commercialize new and exciting treatment modalities in surgical oncology. At the heart of ONKOS SURGICAL is a group of inspiring, enterprising people led by Co-founder and CEO, Patrick Treacy,” said Dr. Gitelis. “ONKOS SURGICAL is committed to developing the next generation of oncological devices and biologics which will enhance the lives of our patients.”


ONKOS SURGICAL Secures $17.6M in Series B Funding Led by Canaan Partners

April 19, 2017, ONKOS SURGICAL, Inc., announced that it closed a $17.6 million round in Series B funding. Canaan Partners led the funding round and existing investors 1315 Capital and 3D Systems also participated. ONKOS will use the new funding to expand its sales, marketing, and R&D platforms to drive aggressive growth and advance the pace of innovation that will dramatically change the lives of surgical oncology patients.

“Every day, musculoskeletal oncologists and their patients are faced with clinical challenges that have been overlooked for too long,” said Patrick Treacy, CEO and Cofounder. “We have the portfolio to deliver meaningful innovation with our advanced 3D printing capabilities, limb restoration technologies, and biologic solutions all enabled with a unique service and surgical planning platform called uDesign™ PATIENT SOLUTIONS. The addition of leading investor Canaan Partners to our roster of investors further validates our opportunity to serve this unique and underserved market,” said Treacy. “The combined intellectual capital and operating experience that Canaan Partners, 1315 Capital and 3D Systems pro vides to our leadership team will enable us to scale our business rapidly and efficiently.”

With Canaan’s investment, Stephen Bloch, General Partner at Canaan Partners, joins the ONKOS SURGICAL Board of Directors. “The ONKOS team brings unmatched experience and commitment to serving the challenges and needs of the surgical oncology community,” said Bloch. “Patients and physicians trust Patrick Treacy and his ONKOS colleagues to translate those clinical needs into innovative products that improve patient care.”


ONKOS ADVOCATES

blog Onkos Surgical is committed to help raise awareness of sarcoma and pediatric cancer through fundraising activities, support of cancer research, and partnerships with organizations and regulatory agencies to advocate for change that will impact the lives of cancer patients.

Sarcoma Foundation of America
The mission of the Sarcoma Foundation of America (SFA) is to advocate for sarcoma patients by funding research and by increasing awareness about the disease. The organization raises money to privately fund grants for sarcoma researchers and conducts education and advocacy efforts on behalf of sarcoma patients. To learn more about the Sarcoma Foundation of America please visit www.curesarcoma.org

American Cancer Society
At the American Cancer Society, we’re on a mission to free the world from cancer. Until we do, we’ll be word about prevention. All so you can live longer — and better. To learn more about the American Cancer Society please visit www.cancer.org


For second year in a row, ONKOS SURGICAL participates in Cancer Action Week in New Jersey

For the second year in a row, members of ONKOS SURGICAL had a productive visit with key members of the New Jersey chapter of the ACS Cancer Action Network, including Mary Hess. Also in attendance for the second year was Sen. Joseph Pennacchio from the 26th district of New Jersey.

“Always a pleasure supporting Cancer Action Week and seeing the passion that Mary Hess of the ACS Cancer Action Network brings to the table.” said Gordon Ballad, VP of Operations at ONKOS SURGICAL “A big thank you to Sen. Pennacchio for taking the time to have a thoughtful discussion and looking for appropriate ways for NJ to continue to support cancer research.”

BlogJan Triani, Senior Director of Regulatory and Quality commented “Surgeons, patients and families deserve a focused company dedicated to surgical oncology. Good enough is simply not good enough for cancer patients and ONKOS SURGICAL is well aligned with the ACS Cancer Action Network of NJ. As always, we were very excited to meet with Sen. Pennacchio to ask New Jersey to continue allocating more money to support cancer research.”

To learn more about the ACS Cancer Action Network, please visit www.acscan.org/states/new-jersey


ONKOS SURGICAL supports Pediatric Oncology at Hackensack Meridian Health

The capstone event for ONKOS Sarcoma Awareness Month was the donation of toys to the boys and girls of the Hackensack Meridian Health Hospital Pediatric Oncology Wing on July 31st. Employee and corporate support for the gifts resulted in over $600 in boxes and boxes of toys. The facility, champion of the Tackle Kids Cancer Foundation, is always in need of toys for their patients as they are cycled through the facility quickly and discarded in order to reduce infection rates in this immune depressed community.

blogMembers of the ONKOS Advocacy Committee were hosted by Amy Glazer, Director of Tackle Kids Cancer and Annual Giving, and Ellen Goldring, Chief of Child Life and Creative Arts Therapy at Hackensack. The group toured the impressive facilities including the out-patient playroom, infusion center, teen game room, in-patient party room, and even the Harry Potter room! The level of in novation, care, and support for the children battling cancer was empowering for the ONKOS team to see first-hand and we look forward to even greater support and partnership in the future.


July was Sarcoma Awareness Month What does Sarcoma Awareness mean to you?

July was Sarcoma Awareness Month. Sarcoma, a type of cancer that occurs in the soft tissue and bones, occurs in 1% of adults with cancer, and 15% of children with cancer. It is among the most life-threatening cancers that children face. That is why ONKOS Surgical is committed to raising awareness of sarcoma and pediatric cancer through partnerships with organizations and regulatory agencies.

The ONKOS Sarcoma Awareness Graphic for the month of July signifies both sarcoma awareness (“yellow”) and hope (“sunflower”).

Throughout the entire month of July, ONKOS SURGICAL employees honored those who have been affected by, and treat sarcoma by answering the question, “What does sarcoma awareness mean to you?”

Dan LibrotDan Librot
Senior Director, Portfolio and Patient Solutions

“Although sarcoma is a rare cancer for adults, it is one of the more common pediatric cancers. Early symptoms can be mistaken for growing pains, leading to late diagnoses and limited treatment options. Educating parents on early warning signs of sarcoma could lead to earlier diagnoses, better outcomes, and saving children’s’ lives.”

Janice FaraoneJanice Faraone
Executive Assistant
“In July, when most kids are excited about swimming, summer camps, camping outdoors, picnics, sports, running around with their friends, there are Sarcoma pediatric in-patients who cannot experience any of those activities. They remain in hospital settings in hopes of a successful treatment plan. Bringing awareness is key to helping surgeons help patients with all the tools available to a successful outcome.”

Kristy SmithKristy Smith
Product Engineer
“The most heartbreaking amongst us to receive a cancer diagnosis are the sweet faces of children. For bone and joint cancers, the highest percentage of cases (26.4%) are diagnosed before the patient turns 20 years old. The median age at diagnosis is 23 years younger than overall cancer ages. Raising awareness of sarcoma can help to bring about research and prevention approaches to combat this harrowing disease.”

MDSteven Gitelis, MD
Orthopaedic Oncologist at Rush University Medical Center (Chicago, IL) Rush Medical College Endowed Professor of Orthopedic Oncology Associate Chief Medical Officer Surgery Past President Medical Staff Medical Director at ONKOS SURGICAL

“While sarcoma is extremely rare this disease can be devastating especially in children. There have been great strides in both treating sarcoma and preserving function. These improvements have been led by a group of specialty centers throughout the United States that are focused on sarcoma. Sarcoma awareness and knowing where to go for treatment or a second opinion is critical for a successful outcome.”

Kristy SmithJackie Dahlmeier
Operations Quality Engineer

“To me, sarcoma awareness means not just informing others about the disease and its impact on the lives of those affected, but also as a way to recruit in an effort to expand the team trying to solve the problem and improve the quality of life of sarcoma patients while doing so.”


A LITTLE ABOUT OUR COMPANY

our-companyPatrick Treacy, Antony Koblish and Adele Oliva saw a unique opportunity for one company to demonstrate leadership and set the agenda for innovation in surgical oncology. Founded in 2015, with best-in-class innovation partners, Onkos Surgical will deliver high quality implants and instruments that meet the unique needs of musculoskeletal tumor patients. From modular segmental systems to customized solutions and patient specific products, Onkos Surgical will partner with surgeons to provide new innovations to help address complex cases. Onkos Surgical has capabilities to increase the speed and delivery of innovation. Onkos Surgical is leveraging new technologies, such as 3D printing, to meet the unique needs of the cancer patient or surgeon. Onkos Surgical will develop products for both hard and soft-tissue applications while continuing to explore strategic partnerships to differentiate our product portfolio. With great customer responsiveness, manufacturing lead-times and quality, our vision is to be able to service and support the needs of the surgical oncologist.

QUALITY AND COMPLIANCE

Quality Policy
Fueled by an organizational culture rooted in integrity, continuous improvement, and perseverance Onkos Surgical will:

  • Provide high quality products and services, delivering exceptional, and consistent customer experiences,
  • Collaborate with surgeons and regulatory agencies to find pathways to provide timely solutions for our customers, and their patients, and
  • Uphold the effectiveness of our quality management system through the pursuit of excellence in regulatory, quality, and health care compliance.

Compliance
To uphold our commitment to delivering the highest standards of compliance rooted in ethics and integrity, Onkos Surgical has established a Compliance Program in accordance with the guidelines published by the Office of Inspector General and U.S. Department of Health and Human Services. Onkos Surgical is dedicated to complying with the Federal Physician Payment Sunshine Act and have established the compliance program in accordance with the AdvaMed Code of Ethics on Interactions with Health Care Professionals (the “AdvaMed Code”).

It is our expectation that employees, distributors and contractors of Onkos Surgical will comply with our Code of Business Conduct and policies established through our compliance program.


blog

Onkos Surgical ® Secures $17.6M in Series B Funding Led by Canaan Partners

Parsippany, NJ. (April 19, 2017) – Onkos Surgical, Inc., a specialty medtech company focused on surgical oncology, today announced that it closed a $17.6 million round in Series B funding. Canaan Partners led the funding round and existing investors 1315 Capital and 3D Systems also participated. Onkos will use the new funding to expand its sales, marketing, and R&D platforms to drive aggressive growth and advance the pace of innovation that will dramatically change the lives of surgical oncology patients.

“Every day, musculoskeletal oncologists and their patients are faced with clinical challenges that have been overlooked for too long,” said Patrick Treacy, CEO and Co-founder. “We have the portfolio to deliver meaningful innovation with our advanced 3D printing capabilities, limb restoration technologies, and biologic solutions – all enabled with a unique service and surgical planning platform called uDesignTM Patient Solutions. The addition of leading investor Canaan Partners to our roster of investors further validates our opportunity to serve this unique and underserved market,” said Treacy. “The combined intellectual capital and operating experience that Canaan Partners, 1315 Capital and 3D Systems provides to our leadership team will enable us to scale our business rapidly and efficiently.”

With Canaan’s investment, Stephen Bloch, General Partner at Canaan Partners, joins the Onkos Surgical Board of Directors. “The Onkos team brings unmatched experience and commitment to serving the challenges and needs of the surgical oncology community,” said Bloch. “Patients and physicians trust Patrick Treacy and his Onkos colleagues to translate those clinical needs into innovative products that improve patient care.”


About Onkos Surgical

Based in Parsippany, NJ., Onkos Surgical is a privately held surgical oncology company founded in 2015. Onkos Surgical believes surgical oncology deserves attention, focus and innovation. Through dedication and strategic partnerships, Onkos Surgical will advance surgical oncology solutions and advocate for and support the surgeons and caregivers that dedicate their lives to the surgical treatment of cancer.

For more information, visit www.onkossurgical.com

About Canaan Partners
Canaan Partners is an early stage venture capital firm that invests in entrepreneurs with visionary ideas. With $4.2 billion under management, a diversified fund and 190 exits to date, Canaan has invested in some of the world’s leading technology and health care companies over the past 30 years. Canaan’s focus areas include fintech, enterprise/SaaS, marketplace, e-commerce, biopharma, digital health and medtech. To learn more about our people and our portfolio, please visit canaan.com.

Until 20 Screening

Thank you to everyone who supported the Onkos Surgical September 15th NJ screening of Until 20. It was a remarkable night as a packed theatre in Morristown was able witness the profound impact James Ragan had in the final years of his life. We were all reminded of the struggles patients, families and caregivers face in confronting this disease. For James, he was relentless in his battle with osteosarcoma. Part of the battle was his unwavering effort to raise the spirits of those around him while leading fundraising efforts for his foundation, Triumph Over Kid Cancer (TOKC). James and the entire Ragan family are incredible people who demonstrated a seemingly boundless love of family and life.

A special thanks to Dr. Val Lewis for introducing us to James’ story and to Jamila Paksima, co-director and co -producer of the film. Jamila’s presence at the screening was much appreciated as she was able to add additional insight during the Q&A session regarding James, his family and the film.

Until 20 Viewing Party Until 20 Screening Until 20 Directors and Onkos President Patrick Treacy

Onkos Surgical will continue to develop innovative products and services to meet the unique needs of the musculoskeletal surgeon and the patients they treat. Through programs like the screening event, we will continue to advocate for patients and their caregivers who face this challenging disease.

For more information about Triumph Over Kids Cancer, please visit http://triumphoverkidcancer.org

Onkos Surgical Supports Difficult Tumor Case with 3D Printed Medical Model

PARSIPPANY, N.J., Feb. 23, 2016 /PRNewswire – Onkos Surgical, a dedicated surgical oncology company founded to bring innovation, advocacy and passion to the surgical oncology marketplace, supported a difficult chondrosarcoma case with the use of a 3D printed medical model.

product1Dr. Francis Patterson, Attending Musculoskeletal Oncology Physician and Assistant Professor at University Hospital in Newark, NJ was preparing for an upcoming difficult tumor surgery when an Onkos Surgical representative asked him if seeing the tumor in 3D would help.

“I was not sure how truly helpful the model would be. However, several times throughout the surgery I referred back to the model. Visualization can be challenging when resecting a tumor in the pelvis. The model was a useful tool for intraoperative planning.” Dr. Patterson said following the surgery.

The patient’s CT scan and imaging technology was used to identify the tumor and surrounding bone and tissues. In just a few days, a replica of the tumor and bone was segmented and manufactured for Onkos Surgical by 3D Systems and shipped to Dr. Patterson for the upcoming surgery.

“It is truly amazing how the advent of 3D printing technology has influenced healthcare. Personalized medicine is going to continue to grow and surgical oncology patients will benefit immensely from the innovation and customization that 3D printing technology enables,” said Onkos Surgical Co-founder and CEO, Patrick Treacy. “We are thrilled to be able to help surgeons and patients in any way we can.”

To order a medical model contact Onkos Surgical at (973) 264-5400.

About Onkos Surgical
Onkos Surgical is a privately held surgical oncology company founded in 2015. Onkos Surgical believes surgical oncology deserves attention, focus and innovation. Through dedication and strategic partnerships, Onkos Surgical is advancing surgical oncology solutions and will advocate for and support the surgeons and caregivers who dedicate their lives to the surgical treatment of cancer.

Onkos Surgical Launches to Focus Exclusively on the Pediatric and Adult Surgical Oncology Market

PARSIPPANY, N.J., Oct. 6, 2015 /PRNewswire/ — Onkos Surgical, an innovative surgical oncology startup founded by Patrick Treacy, Antony Koblish and 1315 Capital, has announced it has closed a Series A round of financing led by 1315 Capital to bring innovation, advocacy and passion to the surgical oncology marketplace.

“Surgical oncology has been an underserved market for some time,” said Patrick Treacy, Founder and CEO, Onkos Surgical. “This complex disease state requires innovation and diverse solutions. Onkos Surgical is 100% focused on bringing new technology and solutions to surgical oncologists. These specialists serve a population where a large portion of patients are children and the broader population may require personalized solutions. Surgeons, patients and families deserve a focused company dedicated to this important cause.”

Onkos Surgical is proud that 1315 Capital saw the unique opportunity for one company to demonstrate leadership and set the agenda for innovation in surgical oncology.

“This investment is particularly compelling,” said Adele Oliva, Partner and Co-Founder of 1315 Capital. “With strong licensing and manufacturing partnerships, a talented and knowledgeable leadership team, and the significant need by patients and surgeons for innovation, we are excited to be a founding investor and partner.”

Onkos Surgical plans to bring value to the company’s initial portfolio of products and services through the development and commercialization of platforms based on personalized medicine and advanced 3D printing capabilities. In addition, Onkos Surgical has secured a partnership with MicroPort Orthopedics to provide Onkos Surgical with a core portfolio of segmental prostheses and with a market leading distribution partner in China.

Onkos Surgical is strategically positioned for innovation and growth with partners that are committed to their vision.

About Onkos Surgical

Onkos Surgical is a privately held surgical oncology start-up founded in 2015. Onkos Surgical believes surgical oncology deserves attention, focus and innovation. Through dedication and strategic partnerships, Onkos Surgical will advance surgical oncology solutions and will advocate for and support the surgeons and caregivers that dedicate their lives to the surgical treatment of cancer.